Aspirin to Target Arterial Events in Chronic Kidney Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

25,210

Participants

Timeline

Start Date

February 25, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Kidney DiseasesCardiovascular DiseasesBleeding
Interventions
DRUG

Aspirin

75mg low dose non enteric coated or dispersible

Trial Locations (1)

NG72UH

RECRUITING

Nottingham Digestive Diseases Centre, Nottingham

All Listed Sponsors
lead

University of Southampton

OTHER

collaborator

University of Nottingham

OTHER

collaborator

University of Warwick

OTHER

collaborator

Nottingham University Hospitals NHS Trust

OTHER

collaborator

East Kent Hospitals University NHS Foundation Trust

OTHER_GOV

collaborator

University of Durham

OTHER

collaborator

Epsom and St Helier University Hospitals NHS Trust

OTHER